B-type Natriuretic Peptide: A Review of Its Diagnostic, Prognostic, and Therapeutic Monitoring Value in Heart Failure for Primary Care Physicians

References

1. ↵
   Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999; 83(2A): 1A–38A.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13: S107–12.

   OpenUrlPubMedWeb of Science
3. ↵
   Stevenson LW, Braunwald E. Recognition and management of patients with heart failure. In: Goldman L, Braunwald E, Zorab R, editors. Primary cardiology. Philadelphia: W B Sanders, 1998: 310–29.
4. ↵
   Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135(5 Pt 1): 825–32.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ 1994; 308: 1615–9.

   OpenUrlFREE Full Text
6. ↵
   Cheung BM, Kumana CR. Natriuretic peptides—relevance in cardiac disease. JAMA 1998; 280: 1983–4.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding as a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun 1989; 159: 1427–34.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 274(5 Pt 2): H1684–9.
9. ↵
   Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991; 12: 315–21.

   OpenUrlAbstract/FREE Full Text
10. ↵
    Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol 1986; 8: 966–70.

    OpenUrlPubMedWeb of Science
11. ↵
    Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37: 379–85.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161–7.

    OpenUrlCrossRefPubMedWeb of Science
13. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349–53.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Yamamoto K, Burnett JC Jr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988–94.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202–9.

    OpenUrlPubMedWeb of Science
16. ↵
    Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288: 1252–9.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    Cheung BM, Kumana CR. Natriuretic peptide—relevance in cardiovascular disease. JAMA 1998; 280: 1983–4.
18. ↵
    Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002; 39: 131–8.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934–41.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228–3.

    OpenUrlCrossRefPubMedWeb of Science
21. ↵
    Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126–30.

    OpenUrlCrossRefPubMedWeb of Science